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Background: Long-acting bronchodilators are first-line treatment for chronic obstructive pul-
monary disease (COPD), and their efficacy on lung function and clinical parameters is recog-
nized.
Objective: To explore the available evidence about the effects of long acting bronchodilators
on Health Related Quality of Life (HRQoL) and Health Status (HS) in clinical research.
Methods: Randomized controlled trials published till December 2012 evaluating HRQoL/HS in
COPD by means of validated questionnaires were analysed.
Results: Fifty-one trials on Long acting b2 agonist (LABA) and Long acting Anticholinergic
(LAMA) met the inclusion criteria. A total of 37,225 moderate-severe COPD patients testing
6 drugs, 12 different devices and 22 different dosages, with a study duration ranging from 4
weeks to 4 years were studied. A statistical significant HRQoL/HS improvement was reached
in 93% of the studies. Nevertheless, the Minimal Important Difference (MID) was reached in
70,6% of the studies considering the difference between baseline and end of the study, and
in 50% when comparing active treatment and placebo.
Conclusions: The data coming from the review support the efficacy of long acting bronchodi-
lators in improving HRQoL/HS of COPD patients. Further research evaluating HRQoL/HS as pri-
mary outcome and according to guidelines on Patient Reported Outcomes is needed.
ª 2013 Elsevier Ltd. All rights reserved.39 0105553524.
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Health Related Quality of Life (HRQoL) and Health Status
(HS) represent the Patient Reported Outcomes (PROs) most
frequently assessed in chronic obstructive pulmonary dis-
ease (COPD). HRQoL refers to the impacts of a disease and
its therapy upon a patient, as perceived by the patient
himself [1e3]. HS is part of the broader concept of HRQoL,
and can be defined as the ability of a subject to be skillful
in a variety of physical, emotional and social activities [4].
Both PROs are assessed by means of validated question-
naires usable for all health conditions (generic question-
naires, e.g. SF-36, EQ5D) [5] or specifically addressed to
COPD (specific questionnaires, e.g. the COPD-specific
version of the St. George’s Respiratory Questionnaire -
SGRQ) [6].
HRQoL and HS are considered relevant in clinical
research, daily practice and regulatory processes [7e16].
The European Medicines Agency (EMA) [14] suggests that,
especially in non life-threatening chronic conditions, when
two drugs show similar efficacy, PROs could be useful in
defining the drug to be recommended. The role of patient’s
perspective is also underlined by the GRADE system [17],
which includes all patients’ preferences and values as
cornerstones in the process of formulating recommenda-
tions, thus contributing to bring scientific research to real
life.
Moreover, the “Global Initiative for Chronic Obstructive
Lung Disease” (GOLD) guidelines have recently proposed
that the classification of severity should consider, besides
pulmonary function or exacerbation history, symptoms or
HS [18].
The aim of the present review was to examine the
available scientific evidences about the effects of long
acting bronchodilators, the mainstay treatment in COPD
[18,19], on HRQoL and HS in order to draw considerations
useful in daily practice and suggest potential areas for
future research.Search strategy
Randomized controlled trials evaluating HRQoL/HS in
COPD by means of validated questionnaires and published
till December 2012 were searched in PubMed, using the
following key words:
B COPD
B Chronic obstructive pulmonary disease
B HRQoL
B Health Status (HS)
B Long acting b2 agonist (LABA) (salmeterol, formoterol,
indacaterol, vilanterol)
B Long acting Anticholinergic Z Long acting muscarinic
antagonist (LAMA) (tiotropium, aclidinium,
glycopyrronium)
For each selected study, the following issues were taken
into account:
 HRQoL/HS Total and domains scores (when available)
 Minimal Important Difference (MID), that is the smallest
difference that patients perceive as important [20]
(reported by the authors or calculated by reviewers
according to figures and tables).
 Presence of complete HRQoL/HS data at each sched-
uled visit
 HRQoL/HS total score mean change at the end of the
study in the treatment group(s)
 Difference in HRQoL/HS total score between active and
placebo group
Results
A total of 44 trials evaluated the impact of LABA and LAMA
on HRQoL and HS with validated questionnaires. Table 1
reports the characteristics of the questionnaires used in
the 44 trials.
Table 1 HRoL/HS questionnaires used in the examined trials.
Questionnaire Number of items Number of
domains
Domains scores Total score/s
Chronic Respiratory Disease
Questionnaire (CRDQ)
20 4  Dyspnea
 Fatigue
 Emotional function
 Mastery
Overall score
EQ-5D 5 questions þ 1 VAS e  Mobility
 Self care
 Usual activities
 Pain/discomfort
 Anxiety/depression
Global health score
SF-36 36 8  Physical functioning
 Role limitations due to
physical health problems
 Bodily pain
 Social functioning
 General mental health
 Role limitations due to
emotional problems
 Vitality
 General health
perceptions
 Physical Component
Summary (PCS)
 Mental Component
Summary (MCS)
St. George’s Respiratory
Questionnaire (SGRQ)
50 3  Symptoms
 Activity
 Impacts
Total score
Visual Simplified Respiratory
Questionnaire (VSRQ)
8 e  Dyspnea
 Anxiety
 Depressed mood
 Sleep
 Energy
 Daily activities
 Social activities
 Sexual life
Global score
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A total of 21 trials fulfilled the selection criteria (8
considering formoterol/arformoterol, 7 salmeterol, 6
indacaterol), with an overall randomized population of
12,213 patients. No studies assessing vilanterol effects on
HRQoL/HS have been published yet. The duration of the
studies ranged from 10 weeks to 1 year, and HRQoL/HS
were always evaluated as secondary outcome (Table 2).
The change in SGRQ Total score from baseline to the end of
the study in patients treated with Long acting b2 agonists
(LABA) and the difference in SGRQ Total score between the
above mentioned change and that in the placebo group are
shown in Figs. 1 and 2.Formoterol
An overall population of 4314 moderateesevere COPD pa-
tients [21] were studied. HRQoL/HS were evaluated in all
studies using the SGRQ. The study duration ranged from 12weeks to 12 months, and comparators of formoterol were
terbutalin [22], salmeterol [23], ipratropium [24,25],
theophylline [26], different formulations of formoterol [27]
and placebo [23e29].
Formoterol was tested as dry powder inhaler (DPI) Aer-
olizer at dose of 12/24 mg bis in die (BID) [2426,27,28],
Novolizer 12/24 mg BID [29], Turbohaler 18 mg BID [25], 9 mg
BID or BID þ 4.5 mg prn [22], and nebulized arformoterol via
PARI LC PLUS nebulizer at doses of 15/20/25 mg BID
[23,27,28] and 50 mg [23].
Randomized patients could receive concomitant treat-
ment with inhaled corticosteroids (ICS) [22e24,26e28] oral
steroids [23,24,27,28], short-acting b2 agonist
[22,23,26,27], xanthine [22,27,29], antileukotrienes [27].
Dahl [24] showed that both formoterol 12 and 24 mg
significantly improved SGRQ total score compared to pla-
cebo (43.5 and 41.7 vs 46.8; PZ 0.009 and P < 0.001), with
a difference exceeding the MID (5.06) only with the 12 mg
dosage. Compared with ipratropium, formoterol 12 mg
showed a statistically significant improvement that
approached the MID (3.79). While formoterol 12 mg
Table 2 Trials evaluating the effect of Long acting b2 agonists and Long Acting Anthicolinergic on HRQoL.
Reference Comparison HRQoL
questionnaires
Randomised
patients
Study
duration
Formoterol/
Arformoterol
Dahl R (2001) Formoterol 12 mg DPI BID
Formoterol 24 mg DPI BID
Ipratropium 40 mg MDI QID
Placebo
SGRQ 780 12 weeks
Rossi A (2002) Formoterol 12 mg DPI BID
Formoterol 24 mg DPI BID
Theophylline 200/300 mg cp
Placebo
SGRQ 854 52 weeks
Wadbo M (2002) Formoterol 18 mg DPI BID
Ipratropium 80 mg pMDI TID
Placebo
SGRQ 183 12 weeks
Campbell M (2005) Formoterol 9 mg DPI BID þ
Terbutaline 0.5 mg prrn
Formoterol 9 mg DPI BID þ
Formoterol 4.5 mg DPI prn
Placebo þ Terbutaline 0.5 mg prrn
SGRQ 657 27 weeks
Baumgarten RA (2007) Arformoterol 15 mg BID PARI Neb
Arformoterol 25 mg BID PARI Neb
Arformoterol 50 mg QD Pari Neb
Salmeterol 42 mg MDI BID
Placebo
SGRQ 724 12 weeks
Gross NJ (2008) Formoterol fumarate inhalation
solution 20 mg BID
Formoterol 12 mg DPI BID
Placebo
SGRQ 351 12 weeks
Welte T (2008) Formoterol 12 mg BID DPI
Formoterol 24 mg OD DPI
SGRQ 321 12 weeks
Hanania NA (2010) Arformoterol 15 mg BID PARI Neb
Arformoterol 25 mg BID PARI Neb
Formoterol 12 mg DPI BID
SGRQ 444 27 weeks
Salmeterol Jones PW (1997) Salmeterol 50 mg MDI BID
Salmeterol 100 mg MDI BID
Placebo
SGRQ, SF-36 283 16 weeks
Di Lorenzo G (1998) Salmeterol 50 mg MDI BID
Theophylline
SF-36 178 52 weeks
Taccola M (1999) Salmeterol 50 mg MDI BID
Theophylline
SF-36 138 52 weeks
Rennard SI (2001) Salmeterol 42 mg MDI BID þ
placebo MDI BID
Ipratropium 36 mg MDI QD
Placebo
CRDQ 405 12 weeks
Gupta RK (2002) Salmeterol 25 mg  2 MDI BID
Placebo
SF-36 33 10 weeks
Chapman KR (2002) Salmeterol 50 mg DPI BID
Placebo
SGRQ 408 24 weeks
Stockley RA (2006) Salmeterol 50 mg DPI BID
Placebo
SGRQ 634 52 weeks
Indacaterol Donohue JF (2010) Indacaterol150 mg DPI OD
Indacaterol 300 mg DPI OD
Tiotropium 18 mg DPI OD
(open label)
Placebo
SGRQ 1683 26 weeks
Dahl R (2010) Indacaterol 300 mg DPI OD
Indacaterol 600 mg DPI OD
Formoterol 12 mg DPI BID
Placebo
SGRQ 1732 52 weeks
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Table 2 (continued )
Reference Comparison
HRQoL
questionnaires
Randomised
patients
Study
duration
Chapman KR (2011) Indacaterol150 mg DPI OD
Indacaterol 300 mg DPI OD
Placebo
SGRQ 415 52 weeks
Kornmann O (2011) Indacaterol150 mg DPI OD
Salmeterol 50 mg DPI BID
Placebo
SGRQ 1002 27 weeks
Kerwin EM (2011) Indacaterol 75 mg DPI OD
Placebo
SGRQ 641 12 weeks
Kinoshita M (2012) Indacaterol 150 mg
Indacaterol 300 mg
Placebo
SGRQ 347 12 weeks
Glycopyrronium D’Urzo A (2011) Glycopyrronium bromide 50 mg SDDPI OD
Placebo sddpi OD
SGRQ 822 26 weeks
Kerwin E (2012) Glycopyrronium bromide 50 mg SDDPI
Tiotropium 18 mg
Placebo
SGRQ 1066 52 weeks
Aclidinium Chanez P (2010) Aclidinium 25, 50, 100, 200, or 400 mg OD
Tiotropium 18 mg
Placebo
SGRQ 464 4 weeks
Jones PW (2011) Aclidinium 200 mg OD
Placebo
SGRQ 1647 42 weeks
Jones PW (2012) Aclidinium 200 mg MDDPI BID
Aclidinium 400 mg MDDPI BID
Placebo
SGRQ 828 24 weeks
Tiotropium Vinken W (2002) Tiotropium 18 mg DPI OD
Ipratropium 40 mg MDI QD
SGRQ, SF-36 535 52 weeks
Donohue JF (2002) Tiotropium 18 mg DPI OD
Salmeterol 50 mg MDI BID
Placebo
SGRQ 623 27 weeks
Brusasco V (2003) Tiotropium 18 mg DPI OD
Salmeterol 50 mg MDI BID
Placebo
SGRQ 1207 27 weeks
Casaburi R (2002) Tiotropium 18 mg DPI OD
Placebo
SGRQ, SF36 921 52 weeks
Casaburi R (2005) Tiotropium 18 mg DPI QD
Placebo
SGRQ 108 25 weeks
Covelli H (2005) Tiotropium 18 mg DPI OD
Placebo
EQ-5D 196 12 weeks
Verkindre C (2006) Tiotropium 18 mg DPI OD
Placebo
SGRQ 100 12 weeks
Um SW (2007) Tiotropium 18 mg DPI OD
Tiotropium 18 mg DPI OD þ
Budesonide 200 mg DPI BID
SGRQ 100 6 weeks
Chan CKN (2007) Tiotropium 18 mg DPI OD
Placebo
SGRQ 913 48 weeks
Johansson G (2008) Tiotropium 18 mg DPI OD
Placebo
EQ-5D 224 12 weeks
Ambrosino N (2008) Tiotropium 18 mg DPI OD
Placebo
SGRQ 234 25 weeks
Tonnel AB (2008) Tiotropium 18 mg DPI OD
Placebo
SGRQ, VSRQ 555 40 weeks
Tashkin DP (2008) Tiotropium 18 mg DPI OD
Placebo
SGRQ 5993 208 weeks
(continued on next page)
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Table 2 (continued)
Reference Comparison
HRQoL
questionnaires
Randomised
patients
Study
duration
Kurashima K (2009) Tiotropium 18 mg DPI OD
Salmeterol 50 mg DPI BID þ
Fluticasone 200 mg DPI BD
SGRQ 84 21 weeks
Bateman ED (2010) Tiotropium 5 mg Respimat OD
Tiotropium 10 mg Respimat OD
Placebo
SGRQ 1990 52 weeks
Hoshino M (2010) Tiotropium 18 mg DPI OD
Tiotropium 18 mg DPI ODþ
Salmeterol 50 mg þ Fluticasone
250 mg DPI BID
SGRQ 36 12 weeks
Bateman ED (2010) Tiotropium 5 mg Respimat OD
Tiotropium 10 mg Respimat OD
Placebo
SGRQ 3991 48 weeks
Abe T (2011) Tiotropium 18 mg DPI OD
Tiotropium 18 mg DPI OD þ
Tulobuterol 2 mg OD td
SGRQ 16 8 weeks
1470 F. Braido et al.improved all SGRQ domains compared both to placebo and
ipratropium, formoterol 24 mg induced a significant
improvement in Symptoms and Activity only when
compared to placebo.
On the contrary, no difference in SGRQ Total Score,
Activity and Impacts were reported between formoterol
12 mg, ipratropium 80 mg and placebo by Wadbo [25]. Only
Symptoms showed an improvement of 9 units in ipratropiumFigure 1 SGRQ total score change from baselbromide vs placebo and 5.7 versus formoterol, but the level
of significance was not reported.
In another trial, both formoterol and theophylline
significantly improved SGRQ total score (formoterol 12 mg
BID P Z 0.030, formoterol 24 mg BID P Z 0.009, and
theophylline P Z 0.03 respectively) compared to placebo.
The SGRQ domains showed different improvements in each
active group: formoterol 12 mg improved Symptomsine to the end of the study in active group.
Figure 2 SGRQ differences in change from baseline to the end of the study between active group and placebo.
LABA/LAMA effects on COPD health status 1471(P Z 0.009), formoterol 24 mg Impacts (P Z 0.016) and
theophylline Activity (P Z 0.003). Neither the significance
of SGRQ score changes for each treatment nor the com-
parison among active treatments effect on HRQoL/HS were
reported [26].
Formoterol in fixed dose plus as needed showed a similar
HRQoL/HS improvement compared to formoterol or pla-
cebo in fixed dose plus terbutaline as needed. Significant
treatment differences were reported at the end of the
study only in Symptoms: formoterol BID þ terbutaline prn
vs. placebo (5.47; P Z 0.002) and formoterol
BID þ formoterol prn vs. formoterol BID þ terbutaline
(4.63; P Z 0.007) [22].
Both formoterol administered once daily (OD) and BID
improved SGRQ total score and domains. The MID was
reached only for the Impacts in patients treated with for-
moterol BID. The between-groups comparison was not re-
ported [29].
Baumgartner [23] showed a dose-related greater
improvement in SGRQ total scores (2.6e3.6 units) with
nebulized arformoterol than placebo (1.2), but inferior to
salmeterol (4.4). The greatest changes were observed in
the Symptoms for all active treatments, with salmeterol as
best performer.
Similarly, Hanania [27] showed an improvement in all
treatment groups, but clinically significant only for for-
moterol 12 mg. The proportion of subjects who reached MID
in SGRQ at week 26 was 45.7% for arformeterol 15 mg, 43.3%
for arformeterol 25 mg and 56.7% for formoterol 12 mg.
A 12-week treatment with nebulized formoterol fuma-
rate and formoterol DPI BID demonstrated that the first
treatment was associated with statistically significant and
clinically meaningful improvements in Total, Symptoms and
Impacts scores compared to placebo (P < 0.03), while no
significant difference was detected in Activity. Formoterol
DPI significantly improved Symptoms, while no significantdifferences were found in Total or domain scores between
active treatments [28].Salmeterol
A total of 2079 moderateesevere patients were randomized
in 7 trials. HRQoL/HS were assessed in 3 studies with SGRQ,
in 3 with SF-36 and in 1 with Chronic Respiratory Disease
Questionnaire (CRDQ) [30]. The duration of the studies
ranged from 10 weeks to 12 months, and comparators of
salmeterol were ipratropium [31], theophylline [32,33] and
placebo [31,34e37].
Salmeterol was tested as MDI 25/42/50/100 mg BID
[31e35] and DPI 50 mg BID [36,37].
Randomized patients could receive concomitant treat-
ments with ICS [31e37], oral steroids [32,34,36,37],
xanthine [34,36,37], short acting anticholinergics [34e38],
cromoglycate, nedocromil, ketotifen [32], or short acting
b2 agonists prn [31e35,37].
In patients belonging to a large cohort study [38], sal-
meterol 50 mg significantly improved SGRQ total and Im-
pacts scores, with changes that exceeded the MID
compared to placebo [34]. No difference was detected in
SGRQ scores between placebo and salmeterol 100 mg. With
the exception of Role Emotional, no significant difference
in SF-36 scores between placebo and active groups was
found. Differences emerged by comparing the two doses of
Salmeterol: changes with salmeterol 50 mg were signifi-
cantly greater than those whit salmeterol 100 mg in SGRQ
Total score and some SF-36 domains, due to a worsening of
HS with salmeterol 100 mg and an improvement with sal-
meterol 50 mg. The same authors published in 2003 a
further analysis of a sub-population of the Boyd’s study,
showing that 59% of patients in the salmeterol 50 mg BID
1472 F. Braido et al.group and only 38% in placebo group reported an improve-
ment of SGRQ exceeding the MID [39].
In a one-year trial both salmeterol and theophylline
significantly improved all SF-36 dimensions, with differ-
ences in favour of Salmeterol group at different time
points: in Physical Functioning after 3 months (10.34 with
Salmeterol vs 3.79 with theophylline, PZ 0.02), in General
Health after 9 months (24.25 vs 14.41; P Z 0.02) and in
Social Functioning after 12 months (15.13 vs 6.84;
PZ 0.04). Moreover, the salmeterol group showed a larger
effect size in all SF-36 domains [32].
A similar study showed an improvement of SF-36 Physical
Functioning and Change in Health in both treatment groups,
with a greater improvement in salmeterol, although the
significance versus comparator and placebo was not re-
ported [33].
CRDQ was used [31] to evaluate the efficacy of salme-
terol and ipratropium versus placebo. The overall CRDQ
score increased in all treatment groups (placebo: 6.8; sal-
meterol: 10.3; ipratropium 9.2), without any significant
difference between them. The proportion of patients who
reached the MID was 38, 46 and 41% for placebo, salmeterol
and ipratropium, respectively.
Salmeterol administered as an add-on drug to Ipratropium
improved all SF-36 dimensions, with the exception of Role
Limitation Emotional, whereas in the placebo group Role
Limitations Emotional, Physical Functioning and Role Limita-
tion Physical did not improve. Themagnitude of improvement
was significantly greater inpatients treatedwith salmeterol in
the dimensions in which both groups ameliorated [35].
In patients treated with inhaled anticholinergic therapy,
salmeterol improved SGRQ Symptoms (P Z 0.003), Impacts
(P Z 0.05) and Total score (P Z 0.05), whereas no signifi-
cant changes were observed with placebo. Nevertheless,
the between-treatment differences in SGRQ were not sta-
tistically significant [36].
In a similar study, the addition of salmeterol to usual
treatment (methylxanthines, short acting anticholinergic
agents, mucolytics) induced an improvement of SGRQ
scores at all visits (4, 28 and 52 weeks), which became
statistically significant at weeks 52 for all dimensions,
compared to placebo [37].Indacaterol
The effect of Indacaterol on HRQoL/HS was explored in 6
trials [40e45] randomizing a total of 5820 patients with
moderateesevere COPD. HRQoL/HS were evaluated always
as secondary outcome using SGRQ. Study duration ranged
from 12 weeks to 12 months, and comparators of indaca-
terol were different dosages of indacaterol itself
[40e42,44], formoterol [40,41], salmeterol [43], tiotropuim
[40,42] placebo [40e44]. Indacaterol was tested as 75 [43],
150 [40,42,43,45], 300 [40e42,45] or 600 mg OD DPI [41].
HRQoL/HS were evaluated always considering patients
with concomitant ongoing treatments represented by ICS
[40e45] and short acting b2 agonist prn [41e45].
In a study performed by Donohue [40], indacaterol 150
and 300 mg improved SGRQ scores, compared to placebo, at
all assessments (P Z 0.01), while no differences were
registered versus tiotropium.At both doses of 300 and 600 mg indacaterol significantly
improved SGRQ total score compared to placebo, with a
greater effect than twice-daily formoterol 12 mg, although
the difference did not reach statistical significance [41].
In a one-year study [42], the change in mean SGRQ total
scores was higher with both indacaterol 150 and 300 mg than
with placebo at all assessments, and significantly higher at
week 26 (150 mg, P Z 0.002; 300 mg, P Z 0.025) and week
44 (PZ 0.002 for both). In a shorter trial, SGRQ total score
was significantly lower than placebo for Indacaterol 150 mg
(P Z 0.005) and indacaterol 300 mg (P Z 0.001), with both
differences exceeding the MID. This improvement was
consistent across the three SGRQ domains (P < 0.05). The
percentage of patients with an improvement from baseline
exceeding the MID were consistently higher in indacaterol
groups than placebo, although the difference reached sta-
tistical significance only for indacaterol 300 mg [45]. Korn-
mann [43] showed that, compared to placebo, Indacaterol
150 mg improved SGRQ scores by a margin that was close to
(week 4) or exceeded (weeks 8e26) the MID, and a supe-
riority to salmeterol (P Z 0.05) at week 12 was reported.
Two identically designed trials tested Indacaterol 75 mg
OD versus placebo. At week 4, the SGRQ total score change
was statistically significant versus placebo only in Study 1
(P < 0.01), while at week 12 this change was significant in
both studies, with differences of 3.8 and 3.6 (P  0.01)
[44].
Long acting anticholinergic(S)
A total of 23 trials fulfilled the selection criteria (2 glyco-
pyrronium, 3 aclidinium, 18 tiotropium), with an overall
randomized population of 22,653 patients. The duration of
the studies ranged from 4 weeks to 4 years. HRQoL/HS were
investigated as primary outcome in 2 out of 23 studies. The
change in SGRQ Total score from baseline to the end of the
study in patients treated with Long acting anticholinergics
and the difference in SGRQ Total score between the above
mentioned change and that in the placebo group are shown
in Figs. 3 and 4.
Glycopyrronium
The effect of glycopyrronium on HRQoL/HS has been
explored in 2 trials [46,47] randomizing 1888 patients with
moderateesevere COPD. HRQoL/HS were assessed as sec-
ondary outcome, using the SGRQ. The comparators of gly-
copyrronium were placebo [46,47] and tiotropium [46].
Glycopyrronium was tested as single dose dry powder
inhaler (SDDPI) [46,47] at dose of 50 mg OD. Randomized
patients could receive concomitant treatments with ICS,
intranasal corticosterid, H1 antagonist, albuterol, salbuta-
mol [46,47].
In the GLOW1 study [46], after 26 weeks, the patients
treated with glycopyrronium bromide 50 mg OD compared
to those treated with placebo reported a significantly lower
SGRQ score (PZ 0.004), with a treatment difference which
does not reach the MID (2.81). Moreover, the percentage
of patients who reached the MID was significantly higher
in the active group vs placebo (56.8% vs 46.3%; odds
ratio 1.58).
Figure 3 SGRQ total score change from baseline to the end of the study in active group.
LABA/LAMA effects on COPD health status 1473The GLOW2 study [47] evaluated the efficacy of glyco-
pirronium bromide compared with placebo and tiotropium
over 52 weeks. At the study end, SGRQ total score was
significantly improved in patients receiving glycopyrronium
(3.32; P < 0.001) and tiotropium (2.84; P Z 0.014)
compared to placebo. Moreover, the percentage of patients
achieving the MID was higher with glycopyrronium (54.3%)
and tiotropium (59.4%) than with placebo (50.8%).
Aclidinium
The effect of aclidinium on HRQoL/HS has been explored in
3 trials [48e50] randomizing 2939 patients with moder-
ateesevere COPD. HRQoL was assessed as secondary
outcome in both studies, using the SGRQ. The study dura-
tion ranged from 4 [48] to 52 weeks [49], and comparators
of aclidinium were placebo [48e50] and tiotropium [48].Figure 4 SGRQ differences in change from baseline to thAclidinium was tested as novel multidose dry-powder
inhaler at dosed of 25, 50, 100 or 200 mg [47,49], and 200 mg
[48e50]. Randomized patients could receive concomitant
treatments with ICS [48e50], oral theophylline [48e50],
anthistamines [48], nedocromil [48], ketotifen [48], inhaled
salbutamol [49,50], oral or parenteral corticosteroids
[49,50], oxygen therapy [50].
In a 4 weeks’ study, Chanez [48] evaluated the effect of
five different doses of aclidinium (25, 50, 100, 200, or 400 mg)
OD compared to placebo or tiotropium 18 mg. An HRQoL
improvement was found with all doses of aclidinium. The
percentage of patients reaching theMID ranged from52.6% in
the 400mg group to 64.4% in the 100mg group.No comparisons
were reported among the different treatment groups.
Jones [49] reported the results of two identical 52-week
studies comparing aclidinium 200 mg and placebo. At the
end of the treatment period, a higher percentage ofe end of the study between active group and placebo.
1474 F. Braido et al.patients of active group reached the MID in the Study 1
(48.1% vs 39.5%, PZ 0.025) but not in Study 2. At week 52,
the mean improvement from baseline in SGRQ total score
was greater for aclidinium compared to placebo in both
studies, with a significant difference shown only in Study 2
(3.49 vs 1.28; P Z 0.021).
The same author explored the effects of two different
doses of aclidinium. The improvement SGRQ total score of
aclidinium 200 mg versus placebo was 3.8 ( P < 0.001)
While with Aclidinium 400 was 4.6 (P < 0.0001). The
percentage of patients who reached the MID at the study
end was significantly higher both with aclidinium 200 mg
(56%; OR 1.83 P< 0.001) and 400 mg (57.3; 1.87 P < 0.001)
compared to placebo [50].Tiotropium
The effect of tiotropium on HRQoL/HS has been explored in
18 trials [51e68] randomizing 17,826 patients with moder-
ateesevere COPD (Table 2). HRQoL/HS were evaluated
using SGRQ in 16 trials, EQ-5D and SF-36 in 2, and the Visual
Simplified Respiratory Questionnaire (VSRQ) in one.
Importantly, HRQoL/HS were investigated as primary
outcome in 2 out of 18 studies [62,65]. The study duration
ranged from 6 weeks to 4 years, and comparators of tio-
tropium were ipratropium [51], salmeterol [52,53], placebo
[53e57,59e63,65,66], tiotropium plus budesonide [58],
salmeterol plus futicasone propionate [64,67], different
doses of tiotropium [65], or tiotropium plus salmeterol/
fluticasone propionate [68].
Tiotropium was tested as 18 mg OD Handihaler
[51e64,67,68] or 5e10 mg OD Respimat [65,66], and
concomitant ongoing treatments were represented by ICS
[51,52,54e57,59,61e64,68], long acting b2 agonists
[56,59,61], oral steroids [51,52,54,55,57e63,65,66], theoph-
ylline [51,54e57,59,61e63,65,66], antileukotrienes [65] and
short acting b2 agonist on demand [52,54e61,63,66e68].
The Dutch/Belgian Tiotropium Study Group described
the combined results of two 1-year trials. The SGRQ total
score improved both in tiotropium and ipratropium group,
but gradually returned towards baseline in patients treated
with the short acting. At the end of the study, a significant
difference in SGRQ total score (P < 0.05) and in the Impact
score (PZ 0.001) was found between the two groups, with
a greater HRQoL/HS improvement in the tiotropium arm.
Moreover, a significantly higher percentage of patients
treated with tiotropium reached the MID after 9 and 12
months (52% versus 35% respectively at 1 year, P Z 0.001).
Patients treated with tiotropium had higher SF-36 in all
physical domains, but at the end of the study the differ-
ences between the two treatment arms were significant
only for Role Physical (P Z 0.033) and Physical Component
Summary (P Z 0.015) [51].
Tiotropium improved SGRQ total score more than pla-
cebo (P < 0.05), whereas this effect was not reached by the
salmeterol group (P Z 0.39). The difference between tio-
tropium and salmeterol (1.6) did not reach statistical
significance. The improvement in SGRQ Impacts score at 6
months was: 5.24 (P < 0.05 vs placebo) in tiotropium,
2.37 (P Z 0.98 vs placebo) in salmeterol and 2.33 in
placebo. The improvements observed with tiotropiumappeared to increase over time, and it was superior to
placebo and salmeterol (P < 0.05) with regard to the pro-
portion of patients reaching the MID, whereas salmeterol
was not statistically different from placebo [52].
In a similar study on 1207 patients [53], the SGRQ total
score improved by 4.2 units in tiotropium group, 2.8 in the
salmeterol, and 1.5 in placebo. A significant difference was
observed only for tiotropium vs placebo (P < 0.01). The
percentage of patients achieving the MID was higher in the
tiotropium group (P < 0.05 for tiotropium vs placebo) in
both studies, while salmeterol was associated with this
finding in one.
Casaburi [54] showed that tiotropium induces a signifi-
cant improvement of SGRQ total score and domains
compared to placebo. A significantly higher percentage of
patients in the tiotropium group (49%) showed an
improvement exceeding MID compared to placebo (30%).
Moreover, patients taking tiotropium had a significant
improvement in Physical health domains of SF-36 compared
to placebo (Physical Function, Role Physical, General
Health and Physical Summary score). No significant differ-
ences in Mental Health Summary were detected apart from
Vitality and Social Function in favour of tiotropium on 4 out
of 5 times of evaluations. 713 patients out of the 921
enrolled in this study underwent a pre-planned withdrawal
of tiotropium. A worsening of SGRQ, although not signifi-
cant, was observed [69].
COPD patients participating in a 8-week pulmonary
rehabilitation program received tiotropium or placebo for
24 weeks. At study end the SGRQ total score in the tio-
tropium group was better than in the placebo. After pul-
monary rehabilitation the SGRQ total score improved by
7.27 units in the tiotropium and 3.41 in the placebo group
although the difference was not significant. The difference
between groups at the end of the study exceeded the MID
and approached the statistical significance (P Z 0.055)
[55]. A post hoc analysis of this study [70] performed on
patients untreated with respiratory medication or treated
only with as-needed short-acting beta-agonists prior to
enrolment, showed an improvement of 5.2 greater in the
tiotropium group compared to placebo (P < 0.05). SGRQ
Activity and Impacts scores improved significantly more in
those treated with tiotropium than with placebo.
The effect of tiotropium on exercise endurance was
assessed in a 12-week study [57] that evaluated HRQoL/HS at
days 1, 42 and 84 of treatment. A statistically and clinically
significant difference in the SGRQ Total and Impacts scores
between tiotropium and placebo was found at day 84 and for
Activity only at day 42. A greater rate of patients treated
with tiotropium (59% vs 35%, P < 0.05) reached the MID.
Also Ambrosino [61] compared tiotropium and placebo in
enhancing the effects of exercise training. The SGRQ Total
score improved after treatment and remained stable in
both groups, and trended towards a lower score on each
test day in tiotropium compared to placebo group. The
changes at study end were 6.0 (33.1 vs 39.1) and 7.3
(31.8 vs 39.1) in the placebo and tiotropium groups,
respectively. Improvements in groups exceeded the MID
both after pulmonary rehabilitation and at the end of the
follow-up period.
Tiotropium was associated with statistically significant
improvements in HRQoL/HS assessed with EQ-5D visual
LABA/LAMA effects on COPD health status 1475analogue scale scores (P < 0.01) and with nonestatistically
significant trends in the five component questions versus
placebo [56]. Viceversa, no difference in EQ-5D between
groups was found in total score between tiotropium and
placebo in a study that lacks of detailed statistical analysis
and patient pre-treatment information [60]. In 913 patients
randomly assigned to receive tiotropium or placebo for 48
weeks, a significant improvement of SGRQ Total score,
(40.9 vs 43.7, P < 0.01), Symptoms score (44.4 versus
49.3, P< 0,01), and Impacts score (28.5 vs 31.3, P < 0.001)
compared to placebo. A score exceeding the MID was ach-
ieved by 53% of patients in the active and 44% in placebo
group (P Z 0.052) [59].
HRQoL/HS were the primary outcome of a trial where
patients treated with tiotropium were compared to pla-
cebo. More patients treated with tiotropium (59.1% vs
48.2%) reached the MID with a mean change of SGRQ total
score from baseline of 8.50 for tiotropium vs 4.32 for
placebo (P < 0.05). Tiotropium, compared to placebo,
significantly improved all SGRQ subscores (P < 0.05) [62].
In the UPLIFT study HRQoL/HS were explored as a sec-
ondary outcome every 6 months using the SGRQ. Significant
differences in favour of tiotropium versus placebo were
observed at all points for the mean change in SGRQ total
score (ranging from 2.3 to 3.3 units, P < 0.001). However,
both at 12 and 48 months the SGRQ improvement did not
reach the MID. A higher proportion of patients in the tio-
tropium than in the placebo group reported an improve-
ment exceeding the MID from baseline at 1 year (49% vs
41%), 2 years (48% vs 39%), 3 years (46% vs 37%) and 4 years
(45% vs 36%) (P < 0.001 for all comparisons) [63]. Pre-
specified subpopulation analyses of the UPLIFT population
have been developed.
Celli showed that, at study end, HRQoL/HS in the tio-
tropium group had not returned to the baseline value [71].
Decramer focused on the 2039 patients with GOLD stage II.
In both tiotropium and control groups, SGRQ total scores
improved relative to baseline over the first 6 months.
Thereafter, a similar, progressive HRQoL/HS deterioration
in both groups was detected. However, at all time points
HRQoL/HS were better in the tiotropium than in the control
group (P  0.006), with differences ranging from 2.7 to 4.0
for the total score [72]. The analysis according to self-
reporting smoking habit showed a SGRQ improvement in
tiotropium greater in continuing smokers (4.63,
PZ 0.0006) than continuing former (2.74, P < 0.001) and
intermittent smokers (0.60, P Z 0.51) [73].
Troosters focused on 810 COPD patients of the UPLIFT
study not receiving other maintenance treatment (LABA,
short acting b2 agonist e SABA, ICS, xanthines) at random-
ization. SGRQ total score improved in the first 6 months in
both groups, with a greater improvement (2.29) in the
tiotropium group, although the MID was not reached.
Moreover, SGRQ total score worsened more slowly in the
tiotropium arm. The difference between groups exceeded
the MID after 25.5 months and remained above the MID
thereafter. Different decline in the Impacts (PZ 0.004) and
Activity scores (P < 0.001) significantly favoured the tio-
tropium group, whereas no difference for Symptoms was
found. At 48 months, the difference in total score was 4.6
units (P < 0.001) in favour of tiotropium [74]. The influence
of gender on long-term responses to tiotropium wasexplored. Both men and women showed statistically sig-
nificant improvements in SGRQ total score. Women re-
ported a baseline worse HRQoL/HS despite a similar disease
severity. Interestingly, total SGRQ score at the study end
tended to improve from baseline with tiotropium more in
women than in men [75].
In 100 patients the effects of tiotropium alone or added
to budesonide was studied. Tiotropium alone was able to
improve the SGRQ total score of 2.8 versus 5.6 when added
to budesonide with a greater proportion of patients
achieving the MID for the last treatment plan (73.2 vs 42.5;
P Z 0.007) [58].
In an open cross-over study, significant improvements in
SGRQ scores were found both for tiotropium and salmeterol/
fluticasone (SFC) (P < 0.001), without differences between
groups. At study end, patients were asked to choose one
treatment. Patients who selected SFC reported a significant
greater improvement in Symptoms (P < 0.05) and in Impacts
(P Z 0.02). Similarly Patients who selected tiotropium
showed a greater improvement in Activity (P Z 0.03) [64].
Bateman performed three trials using tiotropium
administered via Respimat. Two identical studies random-
ized a total of 1990 patients and had HRQoL among the 4
co-primary endpoints. The improvement in SGRQ total
score for both tiotropium doses was statistically superior to
placebo (3.5 [Tio 5 mg- placebo] and 3.8 [Tio 10 mg-
placebo]; P < 0.0001), and the adjusted mean change from
baseline to week 48 exceeded the MID after active treat-
ment in both studies [65].
In another trial 3991 COPD patients were randomised to
receive tiotropium Respimat 5 mg or placebo. Total SGRQ
score improved from baseline in both groups, with a
significantly greater change with tiotropium. Mean differ-
ences in total scores between tiotropium and placebo were
2.2 at week 24 and -2.9 at week 48 (P < 0.0001 at both
time points). The proportion of patients who reached the
MID was significantly higher in the tiotropium group: 50.9%
vs 42% at week 24, and 49.5% vs 41.4% at week 48
(P < 0.0001 at both time points) [66].
Hoshino compared the effects on HRQoL/HS of SFC add
on with tiotropium and tiotropium alone. Treatment with
SFC plus tiotropium, but not tiotropium alone, resulted in
significant improvements of SGRQ scores, compared to
baseline. Between-group comparisons indicated signifi-
cantly greater improvements in SGRQ total and domains
scores (P < 0.05) in triple treatment [67].
A Japanese study compared the effects of inhaled tio-
tropium added to transdermal Tulobuterol versus tio-
tropium alone. Total score and Activity improved
significantly following combination therapy, without any
significant difference between the two groups. Symptoms
improved significantly following tiotropium monotherapy
(33.0 vs 34.3; P < 0.01) while Impacts significantly
improved in combination therapy compared to mono-
therapy ( < 0.05) [68].Long acting beta2 agonists (LABA) plus long-
acting muscarinic antagonist (LAMA)
The effects on HRQoL of LABA/LAMA combination treat-
ment were explored in 6 trials for a total of 2359
1476 F. Braido et al.randomized patients [76e81]. Comparator drugs were for-
moterol [77,79], tiotropium [77,78], salmeterol and SFC
[76,81]. HRQoL/HS were evaluated in all studies as sec-
ondary outcome using SGRQ, and the study duration ranged
from 6 weeks to 12 months.
HRQoL/HS were evaluated considering always patients
with concomitant ongoing treatments represented by ICS
[76e80], SABA prn [79e81] and salbutamol [81].
In 449 patients, randomized to receive tiotropium 18 mg
DPI OD alone or plus SFC 50/250 mg MDI BID or salmeterol
50 mg MDI BID, the association LAMA/LABA and the triple
treatment improved HRQoL more than tiotropium (P < 0.02
and 0.01 respectively) [76].
Tashkin studied 130 patients treated with formoterol
fumarate 20 mg/2 ml Pari Nebulizer BID/tiotropium18 mg DPI
OD or placebo Pari Nebulizer BID/tiotropium 18 mg DPI OD
for 6 weeks. The only statistical and clinical difference
between treatments was observed in SGRQ Symptoms in
favour of formoterol fumarate/tiotropium (PZ 0.004) [77].
847 patients were randomized in 4 groups of treatments
(formoterol 10 mg DPI BID, placebo DPI BID, tiotropium 18 mg
OD DPI/formoterol 10 mg DPI BID, tiotropium 18 mg OD). No
significant differences in SGRQ total score were found be-
tween combined therapy and either monotherapy.
Compared to placebo, all active treatments significantly
improved SGRQ total score (P < 0.005) [78].
No difference after the introduction of formoterol fuma-
rate 20 mg/2 ml Pari Nebulizer BID or placebo as add on
treatment to tiotropium 18 mg DPI OD was found in a 6 weeks
study on 155 patients, although a higher percentage of pa-
tients receivingLAMA/LABA (61%vs21%) reached theMID [79].
A similar trial was performed by Tashkin on 255 patients.
The results of this 12-week study showed that Symptoms was
significantly improved by LAMA/LABA compared to LAMA
alone. However LAMA/LABA group reached the MID for Total,
Symptoms and Impacts scores, while in tiotropium alone the
MID was reached only in the Activity score [80].
The ILLUMINATE study [81] on 523 patients showed that,
after a 26-week treatment with indacaterol plus glyco-
pyrronium via Breezhaler 110/50 mg or salmeterole-
fluticasone 50/500 mg, SGRQ scores improved in both
treatment groups, without any significant difference be-
tween them [81].Discussion
The effects of bronchodilators on patient’s HRQoL/HS is a
crucial issue. A recent review by Karner [82] showed that,
compared to placebo, tiotropium treatment significantly
improved the mean quality of life and increased the num-
ber of participants who reached the MID. Jones [83]
reviewed the efficacy of indacaterol compared to placebo
as a bronchodilator and reported that the MID was achieved
in 2 studies out of 4 in indacaterol 150 mg. On the other
hand, in a review by Chong [84] assessing the relative
clinical effects of tiotropium bromide alone versus LABA
alone, due to a high level of heterogeneity amongst studies,
it was not possible to pool data for SGRQ quality of life
score.
A consistent sample of moderate-severe COPD patients
has been studied testing 6 drugs, 12 different devices, 22different dosages with a study duration ranging from 4
weeks to 4 years. SGRQ has been used in 86% of studies and,
while total score was always reported, domains were
considered in only 60% of cases. A recent review providing a
comprehensive evaluation of the content and psychometric
property of available HRQoL/HS questionnaires for COPD
has recommended the use of specific instruments rather
than generic ones. The authors underline that no optimal
instrument exists, but the choice of a questionnaire should
derive from the aims of the study and from the tool char-
acteristics in terms of questions and domains. This aspect is
missing in the papers we reviewed, since the use of a
questionnaire is not motivated on the basis of the effects
on patients’ life that researchers expected from the
treatment. Each questionnaire focuses on particular areas
and ignores other ones. For example, SGRQ, despite being
one of the instruments with the strongest positive evi-
dences in terms of structural validity and reliability, does
not investigate some domains relevant for COPD patients
such as mobility, social functioning, sleep [85].
The data coming from the above mentioned research
framework support the efficacy of long acting bronchodi-
lators in improving HRQoL/HS of COPD patients. This has
been shown in 7/8 trials testing formoterol, 7/7 salmeterol,
5/6 indacaterol and 17/18 tiotropium, 2/2 glycopyrronium
and 3/3 aclidinium. Pre-post values in active group were
reported in 77%, and 75% of trials indicated the difference
in HRQoL/HS change between active and placebo groups.
Although a statistical significant HRQoL/HS improvement
was reached in 93% of cases, the MID was reached in 70,6%
of the studies considering the difference between baseline
and end of the study, and in 50% of the studies comparing
active treatment and placebo. Taking into consideration
what constitutes important difference in HRQoL scores
beyond the statistical significance of the result is relevant
for interpreting intervention effects on HRQoL. Since only 2
trials [62,65] have explored HRQoL/HS as a primary
outcome, these results must be carefully considered.
Moreover, all randomized patients have been allowed to
take concomitant drugs such as ICS. A recent systematic
review, considering all published RCTs of regular ICS in
COPD, showed a small but statistically significant benefit
for HRQoL/HS using ICS. In particular, in those long-term
studies ICS slowed the rate of decline in HRQoL, with an
effect that appears linear, despite the fact that the
magnitude of this benefit was relatively small (MID -1.22
units/year) [86]. For the above mentioned reasons the ef-
fects of bronchodilators on HRQoL/HS could be greater than
those shown. Interestingly, in some trials comparing
different dosages of the same bronchodilator, the higher
dosage seems related to worse HRQL/HS [24,25,28,35]. This
evidence should be explained considering that, from the
patient’s perspective, the burden of a more challenging
treatment could be detrimental.
Although few trials have been published exploring the
efficacy of LAMA/LABA combination on HRQoL/HS, this
approach demonstrates greater efficacy than individual
drugs alone [87]. Tt is likely that the functional improve-
ment of clinical parameters may imply an improvement in
HRQoL, but, at present, the effect of bronchodilation was
studied only in a limited number of patients. Despite the
positive results, more data are needed. A recent
LABA/LAMA effects on COPD health status 1477metanalysis confirmed the above mentioned results un-
derlying that although the HRQoL/HS improvement was
statistically significant it did not reach the MID, and quality
of the evidence according to GRADE was moderate [88].
The efficacy of bronchodilators on HRQoL/HS as a measure
of overall treatment effectiveness is shown and remains a
crucial outcome in clinical research.
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